

**Supplementary Table S-1.** Within-group effects of anti-hypertensive classes for the management of blood pressure in chronic dialysis patients.

<b>Study</b>	<b>Type of Intervention</b>	<b>Within-group effect Intervention Mean difference (m/s) (95%CI)</b>	<b>Type of comparator</b>	<b>Within-group effect Comparator Mean difference (m/s) (95%CI)</b>
Yu et al. <sup>23</sup>	RAS inhibitor: Ramipril	-0.7 (-2.4; 0.9); p<0.05	Placebo	-0.40 (-2.3, 1.5); p=0.68
Peters et al. <sup>24</sup>	RAS inhibitor: irbesartan	-0.8 (-1.5; 0.0); p=0.05	Placebo	-0.4 (-1.1; 0.4); p=0.30
London et al. <sup>25</sup>	CCB: Nitrendipine	-2.15 (-3.6; -0.71); p<0.01	Placebo	-0.28 (-1.6; 1.02); p=0.66
Saito et al. <sup>26</sup> **	CCB: Nifedipine	-0.19 (-0.27; -0.11); p value not provided	Age-matched control group	+0.91 (0.84; 0.98); p value not provided
London et al. <sup>27</sup>	RAS-inhibitor: Perindopril	-2.0 (-2.5; -1.5); p<0.001	CCB: Nitrendipine	-1.6 (-2.6; -0.72); p<0.001
Sun et al. <sup>28</sup>	RAS-inhibitor: Losartan	-0.9 (-1.0; -0.8); p<0.05	Beta-Blocker: Bisoprolol	-0.4 (-0.6; -0.2); p<0.05
Georgianos et al. <sup>29</sup> #	RAS-inhibitor: Lisinopril	5.5% (-4.6%; 15.6%); p=0.28	Beta-Blocker: Atenolol	-9.3% (-18.5; -0.2%); p=0.04

RAS: renin-angiotensin system; CCB: calcium channel blockers; \*\* absolute values of change in cf-PWV (expressed in m/s) was estimated from Figure 6 and Table 1 of this article using the percentages of change and their standard deviation relative to the mean baseline cf-PWV for both intervention and control groups. # the within-group effect is expressed as percentage of change (%) from baseline (95% confidence interval) calculated from table 3 in the original article.